RecruitingPhase 2NCT05407324

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS)

Sponsor

Corcept Therapeutics

Enrollment

279 participants

Start Date

Nov 15, 2022

Study Type

INTERVENTIONAL

Conditions

Amyotrophic Lateral Sclerosis

Summary

The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dazucorilant, a drug called Dazucorilant 150 mg, and others for people with amyotrophic lateral sclerosis. The study is currently recruiting participants at 35 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDazucorilant 300 mg

300 mg of dazucorilant will be administered once daily in 4 capsules of 75 mg dazucorilant/capsule.

DRUGDazucorilant 150 mg

Dazucorilant and placebo will be administered once daily in 4 capsules, 2 capsules with 75 mg dazucorilant/capsule, and 2 capsules of placebo equivalent.

OTHERPlacebo

Placebo will be administered once daily in capsules of placebo equivalent.

DRUGDazucorilant

Dazucorilant will be administered once daily in 75-mg capsules.

Locations(35)

062

Phoenix, Arizona, United States

278

San Francisco, California, United States

287

Neptune City, New Jersey, United States

353

New York, New York, United States

108

Leuven, Belgium

425

Hamilton, Ontario, Canada

273

Montreal, Quebec, Canada

422

Bron, France

258

Lille, France

257

Limoges, France

261

Marseille, France

423

Montpellier, France

259

Nice, France

262

Paris, France

256

Tours, France

255

Berlin, Germany

270

Bonn, Germany

268

Dresden, Germany

260

Hanover, Germany

265

Jena, Germany

386

München, Germany

267

Rostock, Germany

269

Ulm, Germany

253

Dublin, Ireland

264

Utrecht, Netherlands

283

Bydgoszcz, Poland

385

Krakow, Poland

254

Warsaw, Poland

274

Warsaw, Poland

302

Barcelona, Spain

115

Barcelona, Spain

303

Madrid, Spain

282

Málaga, Spain

194

Valencia, Spain

263

Stoke-on-Trent, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05407324

Related Trials

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

NCT032251441 location

Clinical Procedures to Support Research in ALS

NCT0348927811 locations

Dysphagia, QoL and Attitudes Towards PEG in ALS Patients

NCT053367601 location

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT072900625 locations

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT0732200316 locations